[1]
Hałdys, K.; Latajka, R. Thiosemicarbazones with tyrosinase inhibitory activity. MedChemComm, 2019, 10(3), 378-389.
[2]
Lv, X.; Xia, Y.; Finel, M.; Wu, J.; Ge, G.; Yang, L. Recent progress and challenges in screening and characterization of UGT1A1 inhibitors. Acta Pharm. Sin. B, 2019, 9(2), 258-278.
[3]
Ohtsubo, T.; Shibata, R.; Kai, H.; Okamoto, R.; Kumagai, E.; Kawano, H.; Fujiwara, A.; Kitazono, T.; Murohara, T.; Arima, H. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis. Hypertens. Res., 2019, 42(5), 641-649.
[4]
Liang, X.; Wu, Q.; Luan, S.; Yin, Z.; He, C.; Yin, L.; Zou, Y.; Yuan, Z.; Li, L.; Song, X.; He, M.; Lv, C.; Zhang, W. A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade. Eur. J. Med. Chem., 2019, 171, 129-168.
[5]
Rahman, M.N.; Vukomanovic, D.; Vlahakis, J.Z.; Szarek, W.A.; Nakatsu, K.; Jia, Z. Structural insights into azole-based ınhibitors of heme oxygenase-1: development of selective compounds for therapeutic applications. Curr. Med. Chem., 2018, 25(42), 5803-5821.
[6]
Dos Santos Picanco, L.C.; Ozela, P.F.; de Fatima de Brito Brito, M.; Pinheiro, A.A.; Padilha, E.C.; Braga, F.S.; de Paula da Silva, C.H.T.; Dos Santos, C.B.R.; Rosa, J.M.C.; da Silva, H.M. Alzheimer’s disease: a review from the pathophysiology to diagnosis, new perspectives for pharmacological treatment. Curr. Med. Chem., 2018, 25(26), 3141-3159.
[7]
Zagorska, A.; Partyka, A.; Bucki, A.; Gawalskax, A.; Czopek, A.; Pawlowski, M. Phosphodiesterase 10 ınhibitors - novel perspectives for psychiatric and neurodegenerative drug discovery. Curr. Med. Chem., 2018, 25(29), 3455-3481.
[8]
Zanforlin, E.; Zagotto, G.; Ribaudo, G. An overview of new possible treatments of Alzheimer’s disease, based on natural products and semi-synthetic compounds. Curr. Med. Chem., 2017, 24(34), 3749-3773.
[9]
Boguszewska-Czubara, A.; Budzynska, B.; Skalicka-Wozniak, K.; Kurzepa, J. Perspectives and new aspects of metalloproteinases’ inhibitors in the therapy of CNS disorders: From chemistry to medicine. Curr. Med. Chem., 2019, 26(18), 3208-3224.
[10]
Ferrer, M.D.; Busquests-Cortés, C.; Capó, X.; Tejada, S.; Tur, J.A.; Pons, A.; Sureda, A. Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases. Curr. Med. Chem., 2019, 26(18), 3225-3241.
[11]
Laganà, G.; Barreca, D.; Calderaro, A.; Bellocco, E. Lactate dehydrogenase inhibition: biochemical relevance and therapeutical potential. Curr. Med. Chem., 2019, 26(18), 3242-3252.
[12]
Nabavi, S.M.; Uriarte, E.; Rastrelli, L.; Sobarzo-Sánchez, E. Aporphines and Alzheimer’s disease: Towards a medical approach facing the future. Curr. Med. Chem., 2019, 26(18), 3253-3259.
[13]
Gulcan, H.O.; Mavideniz, A.; Sahin, M.F.; Orhan, I.E. Benzimidazole-derived compounds designed for different targets of Alzheimer’s disease. Curr. Med. Chem., 2019, 26(18), 3260-3278.
[14]
Bonesi, M.; Xiao, J.; Tundis, R.; Aiello, F.; Sicari, V.; Loizzo, M.R. Advances in the tyrosinase inhibitors from plant source. Curr. Med. Chem., 2019, 26(18), 3279-3299.
